地西他滨3d方案治疗骨髓增生异常综合征疗效讨论附两例病例报道  

Discussion of decitabine 3-day program treatment on myelodysplastic syndrome——report of 2 cases

作　　者：宋慧慧[1] 陈宝安[1] 刘苒[1] 高冲[1] 丁家华[1] 孙耘玉[1] 王骏[1] 程坚[1] 赵刚[1] 余正平[1] 鲍文[1] 

机构地区：[1]东南大学附属中大医院血液科,江苏南京210009

出　　处：《东南大学学报（医学版）》2011年第3期474-477,共4页Journal of Southeast University(Medical Science Edition)

基　　金："十一五"国家科技支撑计划课题(2008BAI61B02)

摘　　要：地西他滨作为治疗骨髓增生异常综合征(MDS)的推荐用药,目前有3 d和5 d两种方案。3 d方案剂量较大,人们对其安全性存在担忧。我院近期对2例老年MDS患者进行了地西他滨3 d方案的治疗,安全性较好。As the recommended treatment for myelodysplastic syndrome（MDS）,there were two kinds of programs： 3-day and 5-day.There was concern about the safety of decitabine 3-day program because of its larger dose.Recently,we took the 3-day program of decitabine treatment on two elderly MDS patients safely.

关 键 词：地西他滨 3d方案 骨髓增生异常综合征 病例报告 

分 类 号：R733.3[医药卫生—肿瘤] R453[医药卫生—临床医学]